Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

AG-348

Aliases
Mitapivat
Name
Pyrukynd
INN Name
mitapivat
FDA Approved
Yes

3 clinical trials

1 organization

2 indications

1 document

Indication
Pyruvate Kinase Deficiency
Indication
Thalassemia
Clinical trial
An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects With Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia
Status: Active (not recruiting), Estimated PCD: 2020-08-20
Clinical trial
A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency
Status: Active (not recruiting), Estimated PCD: 2017-05-08
Document
DailyMed Label: Pyrukynd
Organization
Agios Pharmaceuticals, Inc.